Log In
Print this Print this

PB101 (formerly PB1)

  Manage Alerts
Collapse Summary General Information
Company Pivotal BioSciences Inc.
DescriptionLow toxicity analog of interleukin-2 (IL-2)
Molecular Target Interleukin-2 (IL-2)
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today